June 8, 2009  Y's Therapeutics Co., Ltd. appointed Susumu Yamada as board member&CBO, and Akira Murakami & Yoshihiro Ito as Auditors on June 8, 2009.
May 16, 2009  Y’s Therapeutics Co., Ltd have been reduced the paid-in capital and capital reserve.
March 31, 2009  In appointing about the Board of directors and the Auditors.
January 8, 2009  An internet site, Science-Business eXchange which was managed by BioCentury and Nature published that YSPSL would be a potent anti-elilepsy drug.      
November 5, 2008  Y’s Therapeutics Announces Acceptance of CTA to conduct Phase I/II Clinical Trial of YSCMA in France      
September 16, 2008  Y's Therapeutics Completes Phase IIa Trial with YSPSL in Kidney Transplant Patients for Prevention of Ischemic Reperfusion Injury (IRI)
September 10, 2008  Conclusion of Exclusive Licensing Agreement of YSCMA, Humanized Anti-CD26 Monoclonal Antibody, for Development and Sales in Japan
April 1, 2008  In appointing about the Board of directors and the Auditors
February 14, 2008  Y's Therapeutics announces FDA acceptance of IND to conduct Phase I clinical trial for YSCMA in the USA      
January 15, 2008  We have update the employment information at the our website.      
     More  

Top  |  Site Map  |  Access Map  |  Privacy Policy  |  Terms of Use

Y's Philosophy
Y's Products
ニュースリリース
会社案内
パイプライン
プロジェクト概要
パートナリング
採用情報
お問い合わせ
SELECT Y's Therapeutics Y's Therapeutics